Numeco, an affiliate of  the botulinum toxin (BTX) maker Medytox, said the Ministry of Food and Drug Safety has approved Newlux, a next-generation BTX product.

Newlux, Numeco's first BTX preparation, is a next-generation toxin preparation in a freeze-dried powder formulation.

The BTX is characterized by enhanced safety by excluding animal-derived ingredients in the production process, minimizing denaturation of the active neurotoxin protein through a non-chemical treatment process, and improving production yield and quality (purity) by applying the latest manufacturing process.

Numeco plans to produce Newlux at Medytox's Plant 3 and plans to rapidly expand its market share through mass production.

In addition, the company plans to utilize Medytox's experience in growing Meditoxin, Innotox, and Coretox into the country's leading BTX products to expand sales of Newlux and grow it into the country's top BTX product in a short period.

The company is also actively pursuing overseas expansion as it has already completed the establishment of a country-specific license strategy by selecting regions where it can enter quickly in connection with obtaining a license approval in Korea. 

In the future, Numeco will seek to enter advanced markets such as the U.S. and Europe. 

"With the approval of our next-generation toxin product, Newlux, in Korea, we have secured a key driver for future growth," Numeco CEO Joo Hee-seok said. "We will utilize Numeco's strong sales and marketing capabilities to grow Newlux into the number one toxin product in Korea by focusing on completing the mass production system and shortening the launch schedule. "